Ronald Asbury Andrews - 07 May 2021 Form 4 Insider Report for OncoCyte Corp (OCX)

Role: Chief Executive Officer, Director
Signature: /s/ Ronald Andrews
Issuer symbol: OCX
Transactions as of: 07 May 2021
Net transactions value: $0
Form type: 4
Filing time: 02 Jul 2021, 13:59:02 UTC
Next filing: 02 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock, no par value	Options Exercise	$0	+106,221	+93%	$0.000000	219,919	07 May 2021	Direct
transaction	OCX	Common Stock, no par value	Tax liability	$0	-25,873	-12%	$0.000000	194,046	30 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Restricted Stock Units	Options Exercise	$0	-106,221	-100%	$0.000000^*	0	07 May 2021	Common Shares	106,221	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 106,221 Restricted Stock Units.
F2	Restricted Stock Units vested on May 7, 2021.